共 50 条
Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
被引:137
作者:
Yang, Ka
[1
]
Song, Yanling
[1
,2
]
Xie, Haibo
[1
]
Wu, Hao
[1
]
Wu, Yi-Ting
[1
,3
]
Leisten, Eric D.
[1
]
Tang, Weiping
[1
,4
]
机构:
[1] Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA
[2] Shenyang Univ Chem Technol, Dept Pharmaceut Engn, Liaoning 110042, Peoples R China
[3] Natl Cheng Kung Univ, Dept Chem, Tainan 701, Taiwan
[4] Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA
关键词:
HDAC;
Degrader;
PROTAC;
Cereblon;
Thalidomide;
Epigenetic;
UBIQUITIN PROTEASOME SYSTEM;
INDUCED PROTEIN-DEGRADATION;
MULTIPLE-MYELOMA;
SELECTIVE DEGRADATION;
BIOLOGICAL EVALUATION;
PROSTATE-CANCER;
PROTAC DESIGN;
INHIBITORS;
TARGET;
KNOCKDOWN;
D O I:
10.1016/j.bmcl.2018.05.057
中图分类号:
R914 [药物化学];
学科分类号:
100701 ;
摘要:
Histone deacetylases (HDACs) decrease the acetylation level of histones and other non-histone proteins. Over expression of HDACs have been observed in cancers and other diseases. Targeted protein degradation by "hi-jacking" the natural ubiquitin-proteasome-system (UPS) recently emerged as a novel technology to "knock-out" endogenous disease-causing proteins. We applied this strategy to the development of the first small molecule degraders for zinc-dependent HDACs by conjugating non-selective HDAC inhibitors with E3 ubiquitin ligase ligands. Through cell-based assays, we discovered novel bifunctional molecules (dHDAC6) that could selectively degrade HDAC6. Further mechanistic studies indicated that HDAC6 was selectively removed by the UPS.
引用
收藏
页码:2493 / 2497
页数:5
相关论文